World's Best Taiwan Manufacturer of Organic Chlorella, Organic Spirulina and Microalgae Supplements

Best Sale

FEBICO New drug Introduction

Far East Bio-Tec Co., Ltd. is Taiwan New drug supplier and manufacturer with more than 40 years experence. Since 1976, in the Chlorella and Spirulina (both organic certified and natural) available under Febico brand, raw powder, bulk tablets, private labeling and OEM/ODM services, FEBICO has been offering our customers high value New drug production service. With both advanced technology and 40 years experience, FEBICO always make sure to meet each customer's demand.

Result 1 - 3 of 3
  • AGF Whitening Moisturizing Mask
    AGF Whitening Moisturizing Mask

    New whitening experience with specialized ingredients working into each different layers of the skin. Pioneer in hydrating skin with the water magnetic moisturizing mechanism: hydrating, locking and prevent water vaporizing from the skin.

  • AGF Anti-aging, Repairing, Moisturizing Mask
    AGF Anti-aging, Repairing, Moisturizing Mask

    Rejuvenating Factors: Q 10, Acetyl Dipeptide-3 Aminohexanoate, Acetyl Hexapeptide-8, Aminobutyric Acid Moisturizing: AGF water magnetic moisturizing mechanism (hydrating and locking the water in the skin and prevent water vaporizing from the kin)

  • Apomivir®/ New antiviral drug
    Apomivir®/ New antiviral drug

    Far East Bio-tech. Ltd. (FEBICO), founded in 1976, is a top leading brand of microalgae around the world. Far East Microalgae Ind. Co., Ltd. (FEMICO) holds the comprehensive advantages for microalgae cultivation. Our excellent quality are certified HACCP, ISO 22000. Microalgae products are organic, certified by Naturland (an IFOAM accredited association) and USDA National Organic Program (NOP), and Halal product. We consolidate the strength of research, production, and sales for mass production of microalgae and development of derived biomedical products. US and TW FDA have approved investigational new drug (IND) application of Apomivir, New antiviral drugs for patients diagnosed with influenza in 2013 and 2014, respectively. FEBICO's current major development of new drug focuses on the treatment of global emerging infectious diseases and hepatitis-related diseases.

Result 1 - 3 of 3